No Detail Found!

SARS-CoV-2 infection pattern, transmission and treatment: Multi- center study in low to middle-income districts hospitals in Punjab, Pakistan

Author(s)
Sairah Hafeez Kamran Institute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University, Pakistan
Zia Ul Mustafa Department of Pharmacy, District Headquarter Hospital,Pakpattan,Pakistan
Alina Zeeshan Rao Department of Pharmacy, Tehsil Headquarter Hospital,Wazirabad,Pakistan
Syed Shahzad Hasan Department of Pharmacy, University of Huddersfield,Huddersfield,United Kingdom
Farheen Zahoor Department of Pharmacy, Tehsil Headquarter Hospital,Arifwala,Pakistan
Mohammad Umair Sarwar Department of Pharmacy, District Headquarter Hospital,Vehari,Pakistan
Shehroze Khan Department of Pharmacy, District Headquarter Hospital,Vehari,Pakistan
Sannan Butt Department of Pharmacy, Tehsil Headquarter Hospital,Haveli Lakkah,Pakistan
Muhammad Rameez Department of Urology, Jinnah Hospital, Lahore, Pakistan
Muhammad Asif Abbas Department of Pharmacy, District Headquarter Hospital,Layyah,Pakistan
Abstract
Pakistan has reported a substantial number of COVID-19 cases since 2020. A multicenter observational study was conducted to identify the pattern of SARS-CoV-2 infection, transmission, and treatment in patients admitted to seven low to middle-income district hospitals in the Province of Punjab, Pakistan from March to June 2020. A total of 102 patients were recruited. 57 patients tested positive and 45 developed moderate-severe COVID-19 disease. About 67% of the patients in March-April and 93% in May-June have contracted the disease from the local transmission. The mean number of symptoms in SARS-CoV-2 positive patients was significantly higher than suspected patients (6.46 vs 5.04, p=0.003). The number of deaths was low (n=8) with 86% recovery rate. Mild COVID patients received acetaminophen (n=102), azithromycin (n=8), and hydroxychloroquine (n=4) in addition to standard medical care. The treatment provided to moderate-severe cases included acetaminophen (45/45), azithromycin (45/45), Ivermectin (14/45) and corticosteroids (13/45). The mean number of antimicrobials was significantly higher in moderate-severe patients than mild cases (1.80 vs 1.12, p=0.001). Low number of deaths with a high recovery rate was reported. Diabetes was the most common comorbid condition followed by hypertension. Many antimicrobials were prescribed in both mild and moderate-severe cases that require careful review.
Publication Details
Page(s) 1135-1142
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: SUP3, Year: 2021

Request the full text from PASTIC

Keywords
Covid-19, suspected, Azithromycin, confirmed cases, SARS-CoV-2, corticosteroids, Punjab, COVID-19
References
Asghar MS,Kazmi SJH,Khan NA,Akram M,Khan SA,Rasheed U,Hassan M,Memon GM M .2020 .Clinical profiles, characteristics and outcomes of the first 100 admitted COVID 19 patients in Pakistan: A single-center retrospective study in a tertiary care hospital of Karachi. , 12(6) : e8712.
Azar WS,Rachel Njeim R,Fares AH,Azar NS,Azar ST,El Sayed M,Eid AA M .2020 .COVID-19 and diabetes mellitus: How one pandemic worsens the other. Rev. Endocr. Metab, 21(4) : 451-463.
.2020 .Center for diseases control and prevention (CDC). People Who Are at Higher Risk for Severe Illness. , : .
Chen N,Zhou M,Dong X,Qu J,Gong F,Han Y,Yu T .2020 .Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 395(10223) : 507-513.
Conti P and Younes A .2020 .Coronavirus COV19/SARS-CoV-2 affects women less than men: Clinical response to viral infection. J. Biol. Regul, 34(2) : 23812.
Davies NG,Klepac P,Liu Y,Prem K,Jit M K .2020 .Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat. Med, 26 : 1205-1211.
Fatini J,Chahinian H,Yahi N H .2020 .Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal. Int. J. Antimicrob. Agents., 56(2) : 106020.
Forster P,Forster L,Renfrew C,Forster M C .2020 .Explaining phylogenetic network analysis of SARSCoV-2 genomes. Proc. Natl. Acad. Sci., 117(23) : 12524-12525.
Guan W,Ni Z,Yu Hu,Liang WH,Ou CQ,He JX,Liu L,Shan H,China Medical H .2020 .Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med, 382(18) : 1708-1720.
Guo YR,Cao QD,Hong ZS,Tan YY,Chen SD,Jin HJ,Tan KS,Wang DY,Yan Y .2020 .The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak an update on the status. Mil. Med. Res., 7(1) : 11.
Hosseiny M,Kooraki S,Gholamrezanezhad A,Reddy S,Myers L S .2020 .Radiology perspective of coronavirus disease 2019 (COVID-19): Lessons from severe acute respiratory syndrome and Middle East respiratory syndrome. Am J Roentgenol., 214(5) : 1078-1082.
Huang C,Wang Y,Li X,Ren L,Zhao J,Hu Y,Zhang L,Fan G .2020 .Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. , 395(10223) : 497-506.
Khan MIH,Maqsood M,Kataria MA,Sagheer A,Basit A,Khan ZA .2020 .Comparison of features of corona virus in confirmed and unconfirmed patients in Lahore. , 24(2) : 166-172.
Lechien JR,Chiesa-Estomba CM,Place S,Van Laethem Y,Cabaraux P,Mat Q,Huet K,Plzak J,Horoi M,Hans S,Barillari MR,Cammaroto G,Fakhry N,Martiny D,Ayad T,Jouffe L,Hopkins C,Saussez S C .2020 .COVID-19 Task Force of YO-IFOS. Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. J. Intern Med, 288(3) : 335-344.
Million M,Lagier JC,Gautret P,Colson P,Fournier PE,Marani S,Hocquart M,Mailhe M .2020 .Early treatment of COVID-19 patients with hydroxylchloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille. Travel Med Infect Dis, 35 : 101738.
Molina JM,Delaugerreb C,Goffb JL,Mela-Lima B,Ponscarme D,de Castro N D .2020 .No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. , 50(4) : 382-387.
Muhammad A,Owais M,Ali N,Khan H N .2020 .COVID-19 pandemic and precautionary measures in Pakistan. Anaes Pain. Inten. Care, 24(1) : 94-100.
Muralidharan N,Sakthivel R,Velmurugan D,Gromiha MM,Biomol MM .2020 .Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. , : 1-6.
.2020 .National disaster management authority. COVID-19 update. http://web.ndma.gov.pk (Accessed 26th October, : .
Omrani ,Shalhoub S .2015 .Middle East respiratory syndrome coronavirus (MERS-CoV): What lessons can we learn? J Hosp. Infect, 91(3) : 188-196.
Pal M,Berhanu G,Desalegn C,Kandi V .2020 .Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): An update. Cureus, 12(3) : e7423.
Rizzo E .2020 .Ivermectin, antiviral properties and COVID-19: A possible new mechanism of action. Naunyn Schmiedebergs Arch. , 393(7) : 1153-1156.
Tian S,Hu N,Lou J,Chen K,Kang X,Xiang Z,Chen H,Wang D,Ning Liu N,Liu D,Chen G,Zhang Y,Li D,Li J,Lian H,Niu S,Zhang L,Zhang J .2020 .. Characteristics of COVID-19 infection in Beijing. J. Infect, 80 : 401-406.
Waris A,Atta UK,Ali M,Asmat A,Baset A .2020 .. outbreak: Current scenario of Pakistan. New Microbes New Infec, 35(100681) : 1-6.
Wang C,Liu Z,Chen Z,Huang X,Xu M,Zhang Z M .2020 .The establishment of reference sequence for SARS‐CoV‐2 and variation analysis (. J. Med, 92(6) : 667-674.
World Health .2020 .Organization (WHO). Coronavirus disease (COVID-19) situation reports. int/ Accessed 21st June, : .
World Health .2020 .Events how they happen. int/ Accessed 26th October, : .
Xu XW,Wu XX,Jiang XG,Xu KJ,Ying LJ,Ma CL,Li SB,Wang HY,Zhang S,Gao HN,Sheng FJ,Cai HL,Qiu YQ,Li LJ .2020 .Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ, 368 : m792.
0

Citations

0

Downloads

7

Views